Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PCVX

Vaxcyte Inc

Mar 20 • 04:00PM ET

54.72

+0.74 1.37 %

Healthcare • Biotechnology • USA • NASD

Peers: PFE MRNA BNTX NVAX AZN-D JNJ GSK ALNY NVCR VNDA

| Held by: VTI VB IWM XBI VBK VXF IWN IBB VTWO SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-5.71	Insider Own	2.57%	Shs Outstand	143.92M	Perf Week	0.26%
Market Cap	7.88B	Forward P/E	-	EPS next Y	-7.10	Insider Trans	-0.89%	Shs Float	140.23M	Perf Month	-4.54%
Enterprise Value	6.43B	PEG	-	EPS next Q	-1.78	Inst Own	101.33%	Short Float	9.45%	Perf Quarter	27.08%
Income	-766.63M	P/S	-	EPS this Y	-27.49%	Inst Trans	4.73%	Short Ratio	10.04	Perf Half Y	67.90%
Sales	0.00M	P/B	2.67	EPS next Y	1.06%	ROA	-23.30%	Short Interest	13.26M	Perf YTD	18.60%
Book/sh	20.49	P/C	5.05	EPS next 5Y	-1.85%	ROE	-25.59%	52W High	76.61 -28.57%	Perf Year	-26.51%
Cash/sh	10.85	P/FCF	-	EPS past 3/5Y	-17.82% -26.39%	ROIC	-27.41%	52W Low	27.66 97.83%	Perf 3Y	41.40%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	3.67% 5.12%	Perf 5Y	115.35%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-47.05%	Oper. Margin	-	ATR (14)	2.82	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.91	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	44.16	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	7.91	EPS Q/Q	-71.36%	SMA20	-6.13%	Beta	1.42	Target Price	109.00
Payout	-	Debt/Eq	0.04	Sales Q/Q	-	SMA50	-0.17%	Rel Volume	2.96	Prev Close	53.98
Employees	507	LT Debt/Eq	0.04	Earnings	Feb 24 AMC	SMA200	28.39%	Avg Volume	1.32M	Price	54.72
IPO	Jun 12, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-18.32% -	Trades		Volume	3,914,865	Change	1.37%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Reiterated	Needham	Buy	$90 → $110
Sep-12-25	Initiated	Goldman	Neutral	$38
Apr-22-25	Initiated	Cantor Fitzgerald	Overweight
Dec-20-24	Initiated	Goldman	Buy	$135
Dec-07-23	Initiated	Mizuho	Buy	$69
Apr-18-23	Initiated	TD Cowen	Outperform
Jan-03-23	Reiterated	Needham	Buy	$52 → $58
Dec-15-22	Initiated	Guggenheim	Buy	$66
Nov-17-22	Initiated	BTIG Research	Buy	$69
Dec-29-21	Resumed	Jefferies	Buy	$50
Jun-24-21	Resumed	Jefferies	Buy	$50
Jul-07-20	Initiated	Needham	Buy	$40
Jul-07-20	Initiated	Cantor Fitzgerald	Overweight	$55
Jul-07-20	Initiated	BofA Securities	Buy	$37

Show Previous Ratings

Mar-18-26 07:34PM	Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate (GlobeNewswire)
Mar-02-26 03:28PM	Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock. (Barchart)
Feb-25-26 08:30AM	Vaxcyte, Inc. Q4 2025 Earnings Call Summary (Moby)
12:08AM	Vaxcyte Q4 Earnings Call Highlights (MarketBeat)
12:03AM	Vaxcyte Inc (PCVX) Q4 2025 Earnings Call Highlights: Unprecedented Phase 2 Results and ... (GuruFocus.com)
04:05PM	Loading…
Feb-24-26 04:05PM	Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-19-26 03:42AM	Vaxcyte Inc. (PCVX) Confident of Topline Data in Pneumococcal Vaccine Trials (Insider Monkey)
Feb-18-26 07:39PM	Vaxcyte (PCVX) $632.5M Stock Offering Follows Bullish Cantor Fitzgerald Rating (Insider Monkey) +5.33%
08:36AM	Ovintiv to Report Q4 Earnings: What's in Store for the Stock? (Zacks)
Feb-16-26 12:23PM	Impressive Clinical Pipeline Leads to Bullish Sentiment for Vaxcyte (PCVX) (Insider Monkey)
Feb-14-26 03:02PM	Vaxcyte Spotlights VAX-31 Phase 3 Launch, Eyes Adult BLA by End of Next Year at Biotech Summit (MarketBeat)
Feb-11-26 04:05PM	Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines (GlobeNewswire)
Feb-10-26 04:05PM	Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 (GlobeNewswire)
Feb-05-26 04:05PM	Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit (GlobeNewswire)
Feb-02-26 04:05PM	Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +7.15%
11:33PM	Loading…
Jan-29-26 11:33PM	Vaxcyte Announces Pricing of $550 Million Public Offering (GlobeNewswire)
04:06PM	Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jan-26-26 03:14AM	Evercore ISI Rates Vaxcyte Inc. (PCVX) as an Overweight Following CDC Changes to Childhood Vaccination Recommendations (Insider Monkey)
Jan-23-26 10:12AM	Vaxcyte Pushes Next-Gen Pneumococcal Vaccine Into Phase 3 Phase (Benzinga)
Jan-22-26 05:00PM	Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine (GlobeNewswire) +7.19%
Dec-22-25 08:19AM	This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%. (Barrons.com)
06:50AM	What Makes Vaxcyte (PCVX) So Attractive (Insider Monkey)
Dec-08-25 07:00AM	Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults (GlobeNewswire)
Dec-02-25 09:40AM	Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine Rules (Zacks)
Dec-01-25 04:41PM	Moderna Slammed By 'Fear, Confusion' After FDA Alleges Covid Shots Killed 10 (Investor's Business Daily) -8.24%
12:35PM	Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men (MarketWatch)
09:36AM	Moderna Falls as FDA Vows to Impose New Vaccine Requirements (Bloomberg)
Nov-18-25 09:32AM	These 3 Stocks Are Using Buybacks to Signal Market Confidence (MarketBeat)
Nov-10-25 08:16PM	TD Cowen Reiterates "Buy" Rating on Vaxcyte (PCVX) With $50 PT (Insider Monkey) +6.38%
Nov-04-25 04:05PM	Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study (GlobeNewswire)
12:57AM	Loading…
Oct-08-25 12:57AM	Bank of America Securities Maintains a Buy Rating on Vaxcyte (PCVX) (Insider Monkey)
Sep-30-25 02:49PM	What Does Wall Street Think About Vaxcyte (PCVX)? (Insider Monkey)
08:30AM	Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services (GlobeNewswire)
04:12AM	Vaxcyte, Inc. (PCVX) Announces Progress in its VAX-31 Infant Vaccine Study (Insider Monkey)
Sep-12-25 08:55AM	TSCM U.S. Small Cap Growth Strategy Exited Vaxcyte (PCVX) as Its Infant Trial was Less Than Compelling (Insider Monkey)
Sep-03-25 07:30AM	Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose (GlobeNewswire)
Aug-06-25 04:05PM	Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) (GlobeNewswire) -9.06%
Jul-31-25 11:35AM	Vaxcyte, Inc. (PCVX)'s VAX-24 Achieves Phase 2 Success in Infants (Insider Monkey)
Jul-16-25 09:38AM	Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX) (Insider Monkey)
Jul-08-25 08:17AM	Here's Why Vaxcyte (PCVX) Sold Off in Q1 (Insider Monkey)
Jul-02-25 02:47AM	Cantor Fitzgerald Maintains Overweight on Vaxcyte Amid Vaccine Development and ACIP Meeting (Insider Monkey)
May-27-25 09:08AM	Here's Why Vaxcyte (PCVX) Sold Off in Q1 (Insider Monkey)
May-09-25 09:03AM	Is Vaxcyte, Inc. (PCVX) The Best Stock That Will Bounce Back? (Insider Monkey)
May-07-25 04:01PM	Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +8.45%
04:55AM	Fidelity Select Health Care Portfolio Q1 2025 Commentary (Seeking Alpha)
May-03-25 05:30AM	Franklin Growth Opportunities SMA Q1 2025 Commentary (Seeking Alpha)
May-01-25 08:00AM	Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors (GlobeNewswire)
Apr-30-25 06:33PM	Hope Amidst The Madness As Market Avoids A New Low (Seeking Alpha)
Apr-29-25 08:24PM	Is Vaxcyte, Inc. (PCVX) the Best Oversold NASDAQ Stock to Buy Right Now? (Insider Monkey) +5.68%
Apr-11-25 04:21PM	Vaxcyte, Inc. (PCVX): Billionaire Stanley Druckenmiller's Top Stock Pick with Huge Upside Potential (Insider Monkey) +11.27%
Apr-10-25 01:07PM	Vaxcyte Stock Plummets 56% in a Month: Here's the Reason (Zacks) -8.96%
Apr-07-25 08:00AM	ClearBridge Small Cap Growth Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-05-25 11:00AM	Markets Watch Out For Core CPI With Big Banks Set To Report Earnings (Seeking Alpha)
Apr-01-25 12:45PM	Vaxcyte narrow misses in Phase 2 likely to be ok in Phase 3, says Evercore ISI (TipRanks) -14.65%
12:16PM	Rocket acquires Mr. Cooper, Musks xAI acquires X: Morning Buzz (TipRanks)
07:23AM	Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr. (Zacks)
07:19AM	Vaxcyte stock sinks despite Phase II IPD vaccine trial success (Clinical Trials Arena)
Mar-31-25 05:20PM	Vaxcyte: Shares Tanking On Positive Data? Bad Time To Be A Vaccine Developer (Seeking Alpha) -45.64%
04:12PM	Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies' (Investor's Business Daily)
03:39PM	Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity (Seeking Alpha)
09:57AM	Moderna, biotech stocks slide on resignation of FDA official Peter Marks (Yahoo Finance)
09:57AM	Moderna, biotech stocks slide following resignation of FDA official Peter Marks (Yahoo Finance)
09:45AM	Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns (Investor's Business Daily)
07:00AM	Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study (GlobeNewswire)
Mar-30-25 06:30PM	Vaxcyte, Inc. (PCVX): One of the Best Debt Free Mid Cap Stocks to Buy Now (Insider Monkey)
05:00PM	Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study (GlobeNewswire)
04:08PM	Why Vaxcyte, Inc. (PCVX) Is Among the Best Mid Cap Biotech Stocks to Buy (Insider Monkey)
Mar-27-25 11:34AM	Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive (Zacks)
09:44AM	Is Vaxcyte, Inc. (PCVX) the Best Up and Coming Stock to Buy According to Wall Street Analysts? (InsiderMonkey)
Mar-25-25 08:02AM	Vaxcyte (PCVX) Struggled Amid Political Uncertainty (InsiderMonkey)
Mar-20-25 12:00PM	Lazard US Equity Concentrated Portfolio Q4 2024 Commentary (SeekingAlpha)
Mar-07-25 05:35AM	Goldman Sachs Says Its Time to Pull the Trigger on Healthcare Stocks Here Are 2 Names to Pounce on Now (TipRanks)
Mar-03-25 06:50PM	Vaxcyte, Inc. (PCVX): Among the Cash-Rich Mid Cap Stocks to Buy Now (Insider Monkey)
Feb-26-25 11:03AM	Why Vaxcyte, Inc. (PCVX) Is One of the Best Vaccine Stocks to Buy According to Hedge Funds (Insider Monkey)
07:26AM	Q4 2024 Vaxcyte Inc Earnings Call (Thomson Reuters StreetEvents)
02:15AM	Vaxcyte Inc (PCVX) Q4 2024 Earnings Call Highlights: Strong Financial Health and Promising ... (GuruFocus.com)
Feb-25-25 04:01PM	Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
12:30PM	Vaxcyte, Inc. (PCVX): Among the Stocks That Will Go to The Moon According to Analysts (Insider Monkey)
Feb-13-25 04:14PM	It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care (Investor's Business Daily)
Feb-12-25 04:05PM	Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 (GlobeNewswire)
01:25PM	RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care. (Investor's Business Daily)
Feb-08-25 09:22AM	Why Vaxcyte, Inc. (PCVX) Is Among the Best Healthcare Stocks To Buy According to Analysts (Insider Monkey)
Feb-06-25 08:20AM	Vaxcyte advances second stage of Phase 2 study evaluating VAX-31 (TipRanks)
07:22AM	Vaxcyte enters final stage of Phase II pneumococcal vaccine trial in infants (Clinical Trials Arena)
Feb-05-25 08:00AM	Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants (GlobeNewswire)
Jan-30-25 04:05PM	Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-18-25 05:50PM	Why Vaxcyte, Inc. (PCVX) Is One of the Best Russell 2000 Stocks to Invest in According to Analysts? (Insider Monkey)
Dec-23-24 10:11AM	Is Vaxcyte, Inc. (PCVX) the Best Performing Biotech Stock in 2024? (Insider Monkey)
Dec-09-24 07:57AM	What Makes Vaxcyte (PCVX) An Investment Bet? (Insider Monkey)
Dec-04-24 10:03AM	Vaxcyte doses first subject in pneumococcal conjugate vaccine trial in infants (Clinical Trials Arena)
Dec-03-24 08:00AM	Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants (GlobeNewswire)
Nov-27-24 09:29AM	Vaxcyte (PCVX) Surged On Positive Phase 2 Data For Its Drug (Insider Monkey)
Nov-12-24 07:30AM	Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs (GlobeNewswire)
Nov-06-24 12:09AM	Decoding Vaxcyte Inc (PCVX): A Strategic SWOT Insight (GuruFocus.com)
Nov-05-24 04:01PM	Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-01-24 09:13AM	Should You Consider Investing in Vaxcyte (PCVX)? (Insider Monkey)
Sep-14-24 07:47PM	Vaxcyte, Inc. (PCVX): Among Hedge Funds Top Biotech Stock Picks (Insider Monkey)
Sep-11-24 04:05PM	Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-06-24 04:05PM	Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
07:00AM	Obesity drug startup raises $67M; Vors shielded transplant shows promise (BioPharma Dive)

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cowan Elvia	SVP, Finance & CAO	Mar 17 '26	Sale	55.57	1,892	105,147	28,975	Mar 18 07:03 PM
Cowan Elvia	Officer	Mar 17 '26	Proposed Sale	55.89	1,892	105,744		Mar 17 04:16 PM
Cowan Elvia	SVP, Finance & CAO	Mar 11 '26	Option Exercise	25.92	2,500	64,800	33,367	Mar 11 05:23 PM
Cowan Elvia	SVP, Finance & CAO	Mar 11 '26	Sale	58.59	2,500	146,482	30,867	Mar 11 05:23 PM
Wassil Jim	CHIEF OPERATING OFFICER	Mar 10 '26	Sale	58.88	7,395	435,440	166,818	Mar 11 05:23 PM
Cowan Elvia	Officer	Mar 11 '26	Proposed Sale	58.62	2,500	146,550		Mar 11 04:06 PM
Wassil Jim	Officer	Mar 10 '26	Proposed Sale	58.47	7,395	432,386		Mar 10 04:12 PM
Cowan Elvia	SVP, Finance & CAO	Feb 26 '26	Option Exercise	25.92	7,716	199,999	31,931	Mar 02 08:08 PM
Dhaliwal Harpreet S.	Chief Technical Ops Officer	Dec 31 '25	Sale	46.69	9,743	454,891	23,928	Jan 02 04:21 PM
HARPREET DHALIWAL	Officer	Dec 31 '25	Proposed Sale	46.69	9,743	454,893		Dec 31 04:32 PM
Cowan Elvia	SVP, FINANCE	Dec 23 '25	Sale	47.92	11,623	556,972	14,534	Dec 29 05:49 PM
ELVIA COWAN	Officer	Dec 23 '25	Proposed Sale	47.92	11,623	556,972		Dec 23 04:04 PM
Lukatch Heath	Director	Apr 08 '25	Option Exercise	16.78	7,000	117,490	14,175	Apr 10 08:06 AM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Apr 07 '25	Option Exercise	20.93	4,777	99,983	131,950	Apr 09 08:05 AM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Apr 04 '25	Option Exercise	8.96	20,533	183,888	518,775	Apr 07 07:38 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PCVX

Vaxcyte Inc

Upgrade your FINVIZ experience